Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Emblem Corp EMMBF

Healthcare Biotechnology Cannabis
"Emblem Corp is a licensed producer of medical cannabis. It is intended to cultivate and cure cannabis for medicinal use. The group operates in the business segment of production and sale of medical cannabis."


OTCPK:EMMBF - Post by User

Emblem Corp > Is the 70k KG plan still a goal?
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(0)
•••
Comment by daryan1on Oct 19, 2017 5:45pm
87 Views
Post# 26833968

RE:RE:RE:RE:Is the 70k KG plan still a goal?

RE:RE:RE:RE:Is the 70k KG plan still a goal?Like I said... vague. There's a big difference between secondary medical marijuana products vs clinically tested and monitored prescription pharmaceutical drugs. Which is more likely to be prescribed by a doctor, for example? Although Emblem could very well make products that are able to compete with opioids, what are they going to do to compete with companies like Inmed who are already preparing to test their own pharmaceuticals aimed at opioid consumers? 
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities
USER FEEDBACK SURVEY ×

Be the voice that helps shape the content on site!

At Stockhouse, we’re committed to delivering content that matters to you. Your insights are key in shaping our strategy. Take a few minutes to share your feedback and help influence what you see on our site!

The Market Online in partnership with Stockhouse
Later
Participate
Not interested